Literature DB >> 19837202

Patient and general practitioner preferences for the treatment of depression in patients with cancer: how, who, and where?

Laura Hodges1, Isabella Butcher, Annet Kleiboer, Gillian McHugh, Gordon Murray, Jane Walker, Rebecca Wilson, Michael Sharpe.   

Abstract

OBJECTIVE: The objective of this study was to determine and compare patient and general practitioner (GP) preferences for the treatment of depression in patients with cancer.
METHODS: A treatment preference questionnaire was completed by 100 patients who had been diagnosed with both cancer and major depressive disorder and by 86 GPs who had had experience of at least 1 patient with cancer and depression. Participants were asked to rank options for how depression should be treated, who should deliver the treatment, and where treatment should occur.
RESULTS: The top three preferences of patients and GPs for how depression should be treated differed (P<.001). Patients preferred talking treatment alone, whereas GPs preferred a combination of drug and talking treatment. Both patients and GPs preferred treatment to be given by the GP, with older patients having a stronger preference for this. Counselors and cancer nurses were also popular preferences; mental heath professionals were unpopular. The preferred place of treatment was primary care for both patients and GPs, although many patients preferred treatment in the cancer center.
CONCLUSION: Effective and acceptable services for depressed cancer patients need to take patients and GP preferences into account. A model of service that allows a choice of initial treatment modality and collaborative care between primary care and cancer center nurse would meet this requirement.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837202     DOI: 10.1016/j.jpsychores.2009.03.008

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  6 in total

1.  Individual counseling is the preferred treatment for depression in breast cancer survivors.

Authors:  Salene M Wu; Brittany M Brothers; William Farrar; Barbara L Andersen
Journal:  J Psychosoc Oncol       Date:  2014

2.  ReCAP: Would Women With Breast Cancer Prefer to Receive an Antidepressant for Anxiety or Depression From Their Oncologist?

Authors:  Daniel C McFarland; Megan Johnson Shen; Kirk Harris; John Mandeli; Amy Tiersten; Jimmie Holland; Daniel C McFarland; Megan Johnson Shen; Kirk Harris; John Mandeli; Amy Tiersten; Jimmie Holland
Journal:  J Oncol Pract       Date:  2016-01-19       Impact factor: 3.840

Review 3.  Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review.

Authors:  R Kathryn McHugh; Sarah W Whitton; Andrew D Peckham; Jeffrey A Welge; Michael W Otto
Journal:  J Clin Psychiatry       Date:  2013-06       Impact factor: 4.384

4.  Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study.

Authors:  F Desplenter; C Bond; M Watson; C Burton; P Murchie; A J Lee; K Lefevre; S Simoens; G Laekeman
Journal:  Br J Cancer       Date:  2012-10-11       Impact factor: 7.640

5.  Efficacy of psychodynamic short-term psychotherapy for depressed breast cancer patients: study protocol for a randomized controlled trial.

Authors:  Rüdiger Zwerenz; Manfred E Beutel; Barbara H Imruck; Jörg Wiltink; Antje Haselbacher; Christian Ruckes; Heinz Schmidberger; Gerald Hoffmann; Marcus Schmidt; Uwe Köhler; Dagmar Langanke; Rolf-Dieter Kortmann; Susanne Kuhnt; Gregor Weissflog; Yvette Barthel; Katja Leuteritz; Elmar Brähler
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

Review 6.  A critical analysis of the implementation of service user involvement in primary care research and health service development using normalization process theory.

Authors:  Edel Tierney; Rachel McEvoy; Mary O'Reilly-de Brún; Tomas de Brún; Ekaterina Okonkwo; Michelle Rooney; Chris Dowrick; Anne Rogers; Anne MacFarlane
Journal:  Health Expect       Date:  2014-07-24       Impact factor: 3.377

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.